Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 19, Number 3—March 2013

Dispatch

Lymphogranuloma Venereum in Men Screened for Pharyngeal and Rectal Infection, Germany

Karin HaarComments to Author , Sandra Dudareva-Vizule, Hilmar Wisplinghoff, Fabian Wisplinghoff, Andrea Sailer, Klaus Jansen, Birgit Henrich, and Ulrich Marcus
Author affiliations: Author affiliations: Robert Koch-Institute, Berlin, Germany (K. Haar, S. Dudareva-Vizule, A. Sailer, K. Jansen, U. Marcus); European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden (S. Dudareva-Vizule); University of Cologne, Cologne, Germany (H. Wisplinghoff); Laboratoriumsmedizin Köln–Dres. med. Wisplinghoff and Colleagues, Cologne (H. Wisplinghoff, F. Wisplinghoff); Heinrich-Heine-University, Duesseldorf, Germany (B. Henrich)

Main Article

Table 2

Characteristics of MSM patients with CT infection, by LGV status, Germany, 2009–2010*

Characteristic LGV positive, n = 19 LGV negative, n = 95 p value OR (95%CI)
Median age, y (range)
37 (27–55)
30 (19–67)
0.004

Origin n = 16 n = 80

Germany, % (no.)


87.5 (14)
80.0 (64)
0.73†
1.75 (0.34–17.33)
Reported symptoms n = 15 n = 69

None, % (no.)


53.3 (8)‡
73.9 (51)
0.13
2.48 (0.79–7.81)
Median no. male sex partners in past 6 mo (range)

All partners

9 (1–1,000) 5 (1–150) 0.11

Unprotected anal sex partners


1.5 (0–80)
1 (0–150)
0.43

Meeting place for >1 of last 3 partners, % n = 16 n = 82

The Internet

62.5 65.9 0.80 0.86 (0.29–2.62)

Bar/pub/club

50.0 26.8 0.08† 2.73 (0.91–8.15)

Sauna

6.3 13.4 0.68† 0.43 (0.01–3.43)

Sex party

18.8 3.7 0.05† 6.08 (0.71–49.10)

Pornography cinema

0 7.3 0.59† 0.60 (0.00–4.47)

Cruising

0 4.9 1.0† 0.95 (0.00–8.02)

At friends’ homes

12.5 11.0 1.0† 1.16 (0.11–6.52)

Other


6.3
7.3
1.0†
0.84 (0.02–7.81)
Location of sexual contact with last 3 partners, %§ 15 patients/33 answers 57 patients/144 answers

Germany

100.0 95.1 0.33 2.18 (0.29–∞)

Abroad


0
4.9


HIV status

% Positive

57.9 41.1 0.18 1.97 (0.73–5.36)

If positive

Median time since diagnosis, y (range)

4.5 (2.75–13.67) 2.1 (0–20.25) 0.22

HIV therapy, %

n = 8 n = 25

Combination therapy

87.5 52.0 0.11† 6.46 (0.63–312.96)

No therapy

12.5 48.0

Viral load, copies/mL, %

n = 8 n = 22

Undetectable or <1,000

100.0 54.5 0.03† 0.12 (0.00–0.94)

>1,000


0
45.5


History of CT testing and past infections
19
95


CT test ever, yes/no 9/4 27/26 0.35† 2.17 (0.52–10.73)

If yes, when

Past 3 mo

6 11

Past 6 mo

1 3

Past 12 mo


2
5


History of CT infection n = 16 n = 82

Yes, % (no.)

43.8 (7) 12.2 (10) 0.01† 5.60 (1.40–21.24)

If yes, when

Past month

2 0.57† 3.0 (0.26–35.33)

>1 mo


2
3


If history of CT infection in past month, type of current CT infection, no.

Anorectal

4 1

Urethral

0 1

*No. indicates no. persons. MSM, men who have sex with men; CT, Chlamydia trachomatis; LGV, lymphogranuloma venereum; OR, odds ratio.
†Exact logistic regression
‡3 of these patients were from 1 proctological referral practice
§Multiple answers possible.
¶Of 2 pharyngeal LGV cases, the HIV-positive patient was asymptomatic and the HIV-negative patient reported night-sweats.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO